cliantha research



Expertise to Navigate the Complexities of Respiratory Research

Support your respiratory product development with our

- Therapeutic and regulatory experience
- Multi-geographic presence
- Innovative approach

Overview

The Global Burden of Disease data suggests that respiratory diseases contribute to high morbidity and mortality and is third leading cause of death. Chronic obstructive pulmonary disease (COPD) & asthma lead this therapeutic category.

Respiratory clinical studies are complex and challenging studies. When stakes are high, you need partner with deep therapeutic & regulatory expertise.

Cliantha Research is full service global CRO with a unique approach to clinical development & is well suited to manage some of the industry's most complex and challenging respiratory clinical studies.

NORTH AMERICA

BE STUDIES

Type of Product	Studies
MDI	15+
DPI	10+
Intranasal	5+
Respules	5+

PHASE 1 STUDIES

Indication	Studies
Asthma	50+
COPD	20+
Allergic Rhinitis	30+
Healthy Volunteers	100+
Pediatric (adolescents)	1

CLINICAL TRIAL MANAGEMENT

Indication	Studies
Asthma	15+
COPD	20+
SAR	60+
Healthy Volunteers	NAP
Pediatric (adolescents)	3

LATE PHASE

	Molecule	Regulatory	Sites	Patients
Asthma	Albuterol Sulphate 90 mcg Inhalation Powder	USFDA	8	20
	Budesonide + Formoterol 80mcg + 4.5 mcg Aerosol	USFDA	12	60
	Fluticasone Propionate + Salmeterol 100mcg +50mcg Inhalation Powder	NA	4	300
	Cyclobenzaprine Hydrochloride Nasal Spray 0.35% w/v	NA	1	10
	MyTatva application Asthma	DCGI	4	100
Chronic Obstructive Pulmonary Disease (COPD)	Revefenacin 175mcg Inhalation	DCGI	20	244
	Glycopyrronium and Formoterol 18/9.6µg Inhaler	DCGI	14	330
	Tiotropium Bromide 18 µg Inhalation Powder	USFDA	18	225
	Tiotropium Bromide 18 µg Inhalation Powder Device	USFDA	8	100
	MyTatva application COPD	DCGI	4	100
	Tiotropium bromide 18 µg dry powder inhaler	USFDA	31	334
	Tiotropium 18ug Inhalation Powder, Hard Capsule, Inhaler Device	USFDA	1	10
Misc	Cyclobenzaprine Hydrochloride Nasal Spray 0.35% w/v	NA	1	10
	Respiratory Mask	NA	1	25

REGULATORY EXPERIENCE - NORTH AMERICA

- We are abreast of all of the guidelines in respiratory area.
- We have worked with our clients to shorten time-lines by virtue of speaking with FDA OGD with our clients to take slightly different approaches than are in the guidelines. This provides time and cost efficiencies.
- Good safety cover is an important factor for USFDA. Cliantha's proprietary electronic tablet allows close monitoring of patients during long inhalation trials where they are on placebo.

CLIANTHA ADVANTAGE

Contact Cliantha today for more information about how we can enable you to make product launch decisions faster

For more information contact:
info@cliantha.com